Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Update on its Patented DehydraTECH(TM) Technology, Including the Approval of New Patent

  • Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs
  • The company is seeking IND approval from the FDA and has commenced its human HYPER-H21-4 study for hypertension with DehydraTECH-CBD, with results expected in Q3 2022
  • Lexaria is also commencing its human oral nicotine study, NIC-H22-1 to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the US such as ON! and Zyn

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced some positive news that further promotes the company’s goal of creating innovative drug delivery alternatives with its proprietary patented DehydraTECH(TM) technology. Lexaria is making the delivery of drugs quicker, more efficient, and even tasting better.

The company was granted its 25th patent – the first received for the use of its DehydraTECH technology for the enhanced delivery of antiviral drugs. The official word was received from the United States Patent and Trademark Office that on April 26, 2022, patent 11,311,559 for Compositions and Methods For Enhanced Delivery of Antiviral Agents would be issued to Lexaria.

“This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology. This new patent adds to our existing suite of granted patents in the EU, the U.S., India, Japan, and Australia, and continues to build value for Lexaria shareholders and clients,” CEO Chris Bunka explained (https://cnw.fm/PnkiP).

Lexaria is also working on various clinical trial studies, including the recently announced HYPER-H21-4 study. HYPER-H21-4 is a randomized, double-blinded, placebo-controlled, cross-over study in 60 people and also one of the most comprehensive studies taken on by the company. Outcomes for the new study are expected to be available in Q3 2022, and the research is a big step for the company seeking IND (investigational New Drug) approval from the FDA.

Moving forward with the HYPER-H21-4 study was motivated by positive findings in the company’s three other human hypertension clinical studies, which has further supported the pursuit of FDA approval. The studies conducted thus far with hypertension and DehydraTECH have yielded positive results in terms of safety and efficacy (https://cnw.fm/AU4pU) as well as reducing blood pressure (https://cnw.fm/02nuE) and arterial stiffness (https://cnw.fm/lq6wk). All of the past study participants have tolerated DehydraTECH-CBD well, with no adverse effects.

Additionally, Lexaria plans to move forward in dosing for their human NIC-H22-1 study this summer. The study is focused on the oral absorption of nicotine and the comparison will be made between the company’s DehydraTECH-nicotine pouch and other popular products on the market like Zyn and ON! The purpose of the study is to support a safe alternative to harmful pulmonary nicotine application processes.

The company’s DehydraTECH technology works to:

  • Speed up drug delivery
  • Increase bioavailability
  • Increase brain absorption
  • Improves drug potency
  • Reduce drug administration costs
  • Mask unwanted tastes

The company has been advancing its technology since 2016 to demonstrate that bio-absorption of drugs like cannabinoids or nicotine can be five to ten times more effective with a reduced onset time. Lexaria also plans to investigate other markets in 2022 (https://cnw.fm/rafiI).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Archives

Select A Month

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722